What the FDA Isn’t Telling You – SLATE Date: Tue, 27 Sep 2005 Writing in SLATE, Jeanne Lenzer has uncovered evidence demonstrating FDA culpability in helping drug manufacturers conceal vital, life-saving information from the public. In this case, undisclosed suicides in clinical trials testing Eli Lilly’s drug, duloxetine (trade names:…
Credibility Crisis:Survey FDA Scientists – Death in NIH-AIDS Trial – Tauzin Moves to PhRMA Thu, 16 Dec 2004 A credibility crisis in medical research is smoldering: like the Enron accounting scandal, the prescription-drug debacle is a matter of systemic corruption, including gross and widespread failure by the regulatory process. Unlike…
AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New York Times Phase I Drug Trials Used Foster…
Psychopharmacology in Turmoil: David Healy, MD Presentation Columbia + Debate Dr. Joseph Coyne, Ph.D Fri, 9 Dec 2005 Recent reports describing a determined effort to pathologize US infants and toddlers who are being declared to suffer from “severe mental disorders”–the latest, most aggressively marketed diagnosis for children is Bipolar disorder,…
FDA Strong Drug Ties-Less Monitoring – UK MHRA Mon, 6 Dec 2004 A front page article in The New York Times provides a historical perspective to the shift in FDA’s focus (in 1992) from watchdog safeguarding the public against hazardous drugs, food and medical devices, to its current role as…
AHRP Opposes Drug Implants for Psychiatric Patients Those promoting the implants focus on its delivery of continuous sustained drug action to ensure that patients take the drugs they’re prescribed, presumably to prevent relapse. But critics who are familiar with widespread psychotropic drug prescribing abuses recognize the serious potential for harm…
Eli Lilly Prozac Documents: What do They Reveal? Thu, 27 Jan 2005 A report in the BMJ (formerly the British Medical Journal) that relied on internal Eli Lilly documents to challenge Lilly’s claims about the safety of Prozac has stirred a prickly hornet’s nest. [1] The documents show, among other…
Black Box Warnings for Antidepressants – What’s Next? Thu, 16 Sep 2004 NY TIMES Quotations of the Day: A. “I think that we now all believe that there is an increase in suicidal thinking and action that is consistent across all the drugs.” Dr. ROBERT TEMPLE, of the Food and…
AHRP Campaign to Protect Children from Harm Oct 15: FDA Orders Black Box Warnings on Antidepressants labels and Patient Information Guides to Warn about Suicide risk Oct 3: BBC PANORAMA TONIGHT – Taken on Trust – 13 years-Medical Deception Sep 30: GSK Sales Reps told NOT to Divulge Paxill Data…
Additional information as of late Wed Oct 19: Although I was assured that attendance for a presentation by Dr. David Healy (at Columbia University School of Public Health on Oct. 20 at 12:30) would be open to the public, a problem seems to have emerged after an AHRP Infomail about…
FDA Asks Antidepressant drug companies to add Cautions on labels Mon, 22 Mar 2004 The FDA has “requested” drug companies to put prominent warnings on the labels of 10 antidepressant drugs, “to include stronger cautions and warnings about the need to monitor patients for the worsening of depression and the…
Testing Psychotropic Drugs in Children April 30, 2002 David Healy, MD University of Wales College of Medicine April 30th 2002. The background against which this paper is prepared is that in 1997 I organized, chaired and wrote up the recommendations from an International Roundtable Meeting for the British Association for…
